JP2024546759A5 - - Google Patents

Info

Publication number
JP2024546759A5
JP2024546759A5 JP2024534465A JP2024534465A JP2024546759A5 JP 2024546759 A5 JP2024546759 A5 JP 2024546759A5 JP 2024534465 A JP2024534465 A JP 2024534465A JP 2024534465 A JP2024534465 A JP 2024534465A JP 2024546759 A5 JP2024546759 A5 JP 2024546759A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024534465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546759A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/086040 external-priority patent/WO2023111128A1/en
Publication of JP2024546759A publication Critical patent/JP2024546759A/ja
Publication of JP2024546759A5 publication Critical patent/JP2024546759A5/ja
Pending legal-status Critical Current

Links

JP2024534465A 2021-12-16 2022-12-15 イヌインターロイキン-31受容体アルファiiに対するイヌ化抗体 Pending JP2024546759A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163290259P 2021-12-16 2021-12-16
US202163290256P 2021-12-16 2021-12-16
US63/290,259 2021-12-16
US63/290,256 2021-12-16
US202263341443P 2022-05-13 2022-05-13
US63/341,443 2022-05-13
PCT/EP2022/086040 WO2023111128A1 (en) 2021-12-16 2022-12-15 Caninized antibodies to canine interleukin-31 receptor alpha ii

Publications (2)

Publication Number Publication Date
JP2024546759A JP2024546759A (ja) 2024-12-26
JP2024546759A5 true JP2024546759A5 (cg-RX-API-DMAC7.html) 2025-12-19

Family

ID=84923386

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024534474A Pending JP2024546763A (ja) 2021-12-16 2022-12-15 イヌインターロイキン-31受容体アルファiに対するイヌ化抗体
JP2024534465A Pending JP2024546759A (ja) 2021-12-16 2022-12-15 イヌインターロイキン-31受容体アルファiiに対するイヌ化抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2024534474A Pending JP2024546763A (ja) 2021-12-16 2022-12-15 イヌインターロイキン-31受容体アルファiに対するイヌ化抗体

Country Status (7)

Country Link
US (2) US20250340653A1 (cg-RX-API-DMAC7.html)
EP (2) EP4448572A1 (cg-RX-API-DMAC7.html)
JP (2) JP2024546763A (cg-RX-API-DMAC7.html)
AU (2) AU2022409610A1 (cg-RX-API-DMAC7.html)
CA (2) CA3239826A1 (cg-RX-API-DMAC7.html)
MX (2) MX2024007089A (cg-RX-API-DMAC7.html)
WO (2) WO2023111128A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021335500A1 (en) 2020-09-04 2023-05-04 Elanco Us Inc. Palatable formulations
US20250257142A1 (en) * 2024-02-13 2025-08-14 Invetx, Inc. Anti-il-31ra antibodies and uses thereof
WO2026125320A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life
WO2026125322A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. CANINIZED IL31Rα ANTIBODIES WITH AN EXTENDED HALF LIFE
WO2026125321A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
US7696222B2 (en) 2005-08-12 2010-04-13 Merck Frosst Canada Ltd Indole derivatives as CRTH2 receptor antagonists
RS53382B (sr) 2008-08-20 2014-10-31 Zoetis Llc Jedinjenja pirol [2,3-d]pirimidina
WO2010031184A1 (en) 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Azaindole derivatives as crth2 receptor antagonists
AU2009295229B2 (en) 2008-09-22 2014-02-27 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
AU2010331927B2 (en) 2009-12-17 2013-10-10 Merck Canada Inc. Aminopyrimidines as Syk inhibitors
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
AU2014368453B2 (en) 2013-12-20 2020-04-16 Intervet International B.V. Caninized murine anti-canine PD-1 antibodies
EP3526246A1 (en) * 2016-10-17 2019-08-21 Vetoquinol SA Modified antibody constant region
AU2017376398B2 (en) 2016-12-14 2021-07-15 Intervet International B.V. Aminopyrazoles as selective janus kinase inhibitors
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
WO2020116560A1 (ja) * 2018-12-05 2020-06-11 株式会社バイカ・セラピュティクス 抗体のFc領域改変体
CN120005022A (zh) * 2019-01-03 2025-05-16 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
CN110563844A (zh) * 2019-09-04 2019-12-13 华中农业大学 一种抗犬白介素31受体的多克隆抗体及其应用
WO2021123092A1 (en) * 2019-12-20 2021-06-24 Intervet International B.V. Bispecific caninized antibodies for treating atopic dermatitis

Similar Documents

Publication Publication Date Title
JP2022191383A5 (cg-RX-API-DMAC7.html)
JP2022177090A5 (cg-RX-API-DMAC7.html)
JP2023545182A5 (cg-RX-API-DMAC7.html)
JP2023545183A5 (cg-RX-API-DMAC7.html)
JP2024546763A5 (cg-RX-API-DMAC7.html)
JP2024026132A5 (cg-RX-API-DMAC7.html)
JP2021526022A5 (cg-RX-API-DMAC7.html)
JP2022523442A5 (cg-RX-API-DMAC7.html)
HRP20110187T1 (hr) Multispecifične deimunizirane tvari koje vežu cd3
CN115461368A (zh) 抗人白细胞介素-4受体α抗体及其制备方法和应用
WO2022166802A1 (zh) 抗人cd271的单克隆抗体及用途
TW201815825A (zh) 經修飾之抗原結合fab片段及包含其之抗原結合分子
JP2023093753A5 (cg-RX-API-DMAC7.html)
JP2014508511A5 (cg-RX-API-DMAC7.html)
CN115397852B (zh) 工程化抗il-2抗体
JP7533897B2 (ja) 融合タンパク質およびその使用
JP2024516699A5 (cg-RX-API-DMAC7.html)
JP2021509274A (ja) モノクローナル抗体およびその使用法
JP2024540148A5 (cg-RX-API-DMAC7.html)
JP2022545682A5 (cg-RX-API-DMAC7.html)
IL310419A (en) Human interleukin-4 receptor alpha antibodies
JP2016520595A5 (cg-RX-API-DMAC7.html)
JP2024528935A5 (cg-RX-API-DMAC7.html)
JP2024516098A5 (cg-RX-API-DMAC7.html)
JP2025508317A5 (cg-RX-API-DMAC7.html)